DHR

Danaher remains a high-quality industrial/life-science platform. Gross margin is a rich 59.1% and operating margin 19.1%, the FY2025 books carry an unqualified Ernst & Young opinion with internal control over financial reporting deemed effective (per the 10-K), and cash generation is genuinely strong: operating cash flow of $6.42B against just $1.16B of capex implies roughly $5.3B of free cash flow — well above reported net income of $3.61B, the gap being non-cash amortization of acquired intangibles (D&A was $2.17B). The balance sheet is sound: equity of $52.5B, cash more than doubled to $4.62B (+122%), and current assets of $12.8B cover current liabilities of $6.81B nearly 1.9x.

The problem is the earnings trajectory. Net income has fallen every single year since the 2022 peak — $7.21B (2022) → $4.76B → $3.90B → $3.61B (2025), a ~50% decline — while revenue has stagnated near $24B (FY2025 $24.6B, +2.9%). Net margin has compressed from ~27% in 2022 to 14.7% today, and diluted EPS slipped again to $5.05 (-4.5%). Return on equity is only 6.9% — strikingly low for a company built on the Danaher Business System — because the acquisition-heavy equity base (mostly goodwill/intangibles plus $46.9B of retained earnings) isn't yet earning its keep. Long-term debt also rose 18.8% to $18.4B.